<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:protege="http://protege.stanford.edu/plugins/owl/protege#" xmlns:xsp="http://www.owl-ontologies.com/2005/08/07/xsp.owl#" xmlns:Thesaurus="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>                               NIH Public Access <br />                                Author Manuscript <br />                                Cell Metab. Author manuscript; available PMC 2013 November 07. <br />                            Published final edited form as: <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                             Cell Metab. 2012 November 7; 16(5): 645&#226;&#8364;&#8220;657. doi:10.1016/j.cmet.2012.10.001. <br />  <br />  <br />  <br />                            mTOR Regulates Cellular Iron Homeostasis through <br />                            Tristetraprolin <br />                            Marina Bayeva1, Arineh Khechaduri1, Sergi Puig2, Hsiang-Chun Chang1, Sonika Patial3, <br />                            Perry J. Blackshear3, Hossein Ardehali1,* <br />                            1Feinberg Cardiovascular Research Institute, Northwestern University School Medicine, <br />  <br />                            Chicago, IL 60611, USA <br />                            2Departamento Biotecnolog&#195;&#173;a, Instituto Agroqu&#195;&#173;mica y Tecnolog&#195;&#173;a Alimentos (IATA- <br />                            CSIC), P.O. Box 73, E-46100 Burjassot, Valencia, Spain <br />                            3Laboratory Signal Transduction; National Institute Environmental Health Science; Research <br />                            Triangle Park, NC 27709, USA <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                            SUMMARY <br />                                  Iron essential cofactor unique redox properties. Iron regulatory proteins 1 2 <br />                                  (IRP1/2) established important regulators cellular iron homeostasis, little is <br />                                  known role pathways process. Here report mammalian target <br />                                  rapamycin (mTOR) regulates iron homeostasis modulating transferrin receptor 1 (TfR1) <br />                                  stability altering cellular iron flux. Mechanistic studies identify tristetraprolin (TTP), protein <br />                                  involved anti-inflammatory response, downstream target mTOR binds and <br />                                  enhances degradation TfR1 mRNA. We TTP strongly induced iron <br />                                  chelation, promotes downregulation iron-requiring genes mammalian yeast cells, <br />                                  modulates <span id='am-8' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-9' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-10' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-11' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-12' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-13' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-14' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-15' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-16' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-17' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-18' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-19' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-20' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-21' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-22' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-23' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-24' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-25' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-26' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-27' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-28' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-29' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-30' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-31' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-32' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-33' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-34' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-35' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-36' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-37' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-38' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-39' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-40' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-41' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-42' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-43' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-44' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-45' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-46' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-47' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-48' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-49' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-50' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-51' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-52' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-53' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-54' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-55' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-56' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-57' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-58' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-59' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-60' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-61' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-62' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-63' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-64' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-65' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-66' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-67' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-68' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-69' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-70' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-71' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-72' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-73' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-74' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-75' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-76' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-77' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-78' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-79' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-80' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-81' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-82' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-83' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-84' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-85' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span>survival</span> low-iron states. Taken together, data uncover link between <br />                                  metabolic, inflammatory, iron regulatory pathways, point existence a <br />                                  yeast-like TTP-mediated iron conservation program mammals. <br />  <br />  <br />                            INTRODUCTION <br />                                               Iron deficiency anemia affects quarter world&#226;&#8364;&#8482;s population (WHO, 2008), the <br />                                               mechanisms iron regulation remain largely unexplored. Iron essential <span id='am-1' about='Thesaurus:Micronutrient' typeof='owl:Thing'>micronutrient</span> <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                               required fundamental biological processes including oxygen delivery, protein synthesis, <br />                                               DNA replication oxidative phosphorylation (Arredondo Nunez, 2005). However, <br />                                               ability iron easily gain lose electrons facilitates production reactive <br />                                               oxygen species (ROS) Fenton reaction (Aisen et al., 2001). Thus, iron levels be <br />                                               tightly controlled cellular systemic levels deregulation iron homeostasis is <br />                                               associated aging, metabolic disorders cancer (Aisen et al., 2001; Altamura and <br />                                               Muckenthaler, 2009; Torti Torti, 2011; Weinberg, 2010). <br />  <br />  <br />  <br />  <br />                            &#194;&#169; 2012 Elsevier Inc. All rights reserved. <br />                            * <br />                             Correspondence: h-ardehali@northwestern.edu. <br />                            Publisher&apos;s Disclaimer: This PDF file unedited manuscript accepted publication. As service our <br />                            customers providing early version manuscript. The manuscript undergo copyediting, typesetting, review of <br />                            resulting proof published final citable form. Please note production process errors be <br />                            discovered affect content, legal disclaimers apply journal pertain. <br />                            The authors declare conflicts interest <br />                             Bayeva et al.                                                                                             Page 2 <br />  <br />  <br />                                            Maintenance cellular iron homeostasis dependent RNA-binding iron regulatory <br />                                            proteins 1 2 (IRP1/2) activated iron-deficient conditions. IRP1/2 <br />                                            function restore iron levels through: 1) stabilization transferrin receptor 1 (TfR1) <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            mRNA increased iron uptake, 2) mobilization cellular iron stores, 3) reduction in <br />                                            cellular iron export suppression ferroportin 1 (Fpn1), cellular iron <br />                                            exporter identified date (Hentze et al., 2010; Rouault, 2006; Wang Pantopoulos, <br />                                            2011). Additionally, iron conservation response recently described S. <br />                                            cerevisiae coordinated expression tandem zinc finger (TZF) proteins Cth1p and <br />                                            Cth2p causes destabilization mRNAs nonessential iron-containing proteins and <br />                                            libration iron use vital processes (Pedro-Segura et al., 2008; Puig et al., 2005; Puig <br />                                            et al., 2008). A mammalian homolog Cth1p/Cth2p, tristetraprolin (TTP), been <br />                                            extensively studied context immunosuppression (Baou et al., 2009), role in <br />                                            iron regulation known. <br />  <br />                                            Mammalian target rapamycin (mTOR) important sensor cellular energy state and <br />                                            major hub integration environmental cues (Howell Manning, 2011; Sengupta et <br />                                            al., 2010). The complex activated energetically favorable, low-stress states while <br />                                            adverse conditions, starvation, cytotoxic insults DNA damage, act inhibit <br />                                            mTOR signaling promote survival conservation cellular resources (Dunlop <br />                                            Tee, 2009; Soliman, 2005). Many processes governed mTOR dependent on <br />                                            iron co-factor require steady supply metal. There appears a <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            link iron homeostasis mTOR, clinical use rapamycin associated with <br />                                            development microcytic anemia mechanistically distinct anemia of <br />                                            chronic disease (Kim et al., 2006; Maiorano et al., 2006; Sofroniadou et al., 2010). Here, we <br />                                            establish mTOR pathway regulator iron homeostasis acts modulation <br />                                            iron transporters alteration cellular iron flux. Moreover, identify TTP a <br />                                            target mTOR which, part, modulates iron-regulatory effects through <br />                                            destabilization TfR1 mRNA. <br />  <br />                               RESULTS <br />                               mTOR regulates cellular iron homeostasis <br />                                            mTOR activation stimulates important anabolic processes depend the <br />                                            presence iron cofactor; therefore, hypothesized mTOR play role the <br />                                            regulation cellular iron availability utilization. <span id='am-7' about='protege:TO' typeof='owl:Thing'>To</span> test this, modulated mTOR <br />                                            signaling wild type (WT) mouse embryonic fibroblasts (MEFs) H9c2 cardiac <br />                                            myoblasts followed quantification heme non-heme iron content. Rapamycin <br />                                            effectively inhibited mTOR signaling cell lines (Figure 1A), assessed the <br />                                            ablation pS6 expression. Treatment rapamycin led significant increase both <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            non-heme heme iron content MEFs (Figure 1B S1A) H9c2 cells (Figure <br />                                            S1B,C). Consistent elevation iron levels, protein content ferritin light chain, an <br />                                            iron storage molecule, significantly increased rapamycin treatment WT MEFs <br />                                            (Figure S1D). Increased heme levels likely inhibition heme degradation, as <br />                                            mRNA levels heme oxygenase 1 (HMOX1) significantly decreased, the <br />                                            expression key heme synthetic enzymes, &#206;&#180;-aminolevulinic acid synthase 1 (ALAS1) and <br />                                            ferrochelatase, remained unchanged (Figure S1E). To activate mTOR, used TSC2 <br />                                            <span id='am-164' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-165' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-166' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-167' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-168' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-169' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-170' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-171' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-172' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-173' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-174' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-175' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-176' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-177' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-178' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-179' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-180' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-181' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-182' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-183' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-184' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-185' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-186' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-187' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-188' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-189' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-190' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-191' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-192' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-193' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-194' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-195' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-196' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-197' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-198' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-199' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-200' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-201' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-202' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-203' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-204' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-205' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-206' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-207' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-208' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-209' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-210' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-211' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-212' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-213' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-214' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-215' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-216' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-217' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-218' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-219' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-220' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-221' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-222' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-223' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-224' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-225' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-226' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-227' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-228' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-229' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-230' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-231' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-232' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-233' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-234' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-235' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-236' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-237' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-238' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-239' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-240' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-241' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span>knockout</span> MEFs upstream inhibitor pathway genetically deleted and <br />                                            pS6 levels increased (Figure 1A). The knockout MEFs transfected an <br />                                            pEF6 vector (referred TSC2 KO-V MEFs) pEF6/TSC2 vector to <br />                                            reconstitute TSC2 expression knockout MEFs (TSC2 KO-TSC2 MEFs), followed by <br />                                            selection blasticidin generate stable transgenic cell lines described (Zhang et al., <br />                                            2003). Constitutive activation mTOR TSC2 KO-V MEFs decreased heme non- <br />  <br />  <br />                                                Cell Metab. Author manuscript; available PMC 2013 November 07. <br />                             Bayeva et al.                                                                                            Page 3 <br />  <br />  <br />                                            heme iron, rapamycin restored levels control (Figure 1C S1F), <br />                                            indicating observed changes mTOR modulation. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            To determine changes cellular iron resulted alterations iron import, we <br />                                            measured uptake radioactive iron (55Fe) mTOR modulation. Unexpectedly, <br />                                            rapamycin treatment significantly reduced iron uptake, TSC2 KO-V MEFs TSC2 <br />                                            siRNA-treated H9c2 myoblasts displayed enhancement iron uptake 60 minutes of <br />                                            incubation (Figure 1D,E S1G,H). The differences persisted 24 hours of <br />                                            growth 55Fe cell lines (Figure 1F,G S1I,J). These results suggest that <br />                                            inhibition mTOR results cellular iron accumulation despite reduction iron uptake, <br />                                            mTOR activation opposite effect. <br />  <br />                                            We studied mechanism observations measuring expression genes <br />                                            involved iron regulation MEFs H9c2 (Anderson Vulpe, 2009; Hentze et al., <br />                                            2010). Consistent decreased iron uptake, rapamycin significantly reduced the <br />                                            mRNA protein levels transferrin receptor 1 (TfR1) required uptake of <br />                                            transferrin-bound iron (Figure 2A,C). Additionally, TfR1 levels reduced MEFs and <br />                                            H9c2 treated Torin-1, specific inhibitor mTOR pathway (Figure S2A). <br />                                            However, mRNA protein levels iron exporter, Fpn1, reduced by <br />                                            rapamycin Torin-1 (Figure 2B,C, Figure S2A). Consistently, mTOR activation <br />                                            increased expression TfR1 Fpn1, rapamycin suppressed effect (Figure <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            2D). These results suggest mTOR inhibition leads coordinated reduction the <br />                                            expression TfR1 Fpn1, resulting net accumulation cellular iron, mTOR <br />                                            activation opposite effect. <br />  <br />                                            In addition effects TfR1 Fpn1, rapamycin led global suppression many <br />                                            iron-regulatory genes MEFs H9c2, consistent reduction cellular iron flux, <br />                                            opposite observed activation mTOR (Figure S2B&#226;&#8364;&#8220;E). On contrary, we <br />                                            downregulation genes involved regulation cellular iron upon <br />                                            rapamycin treatment WT MEFs (Figure 2E), suggesting effects iron regulatory <br />                                            network specific, represent artifact generalized transcriptional <br />                                            repression. <br />  <br />                               TfR1 target mTOR <br />                                            Concurrent decrease expression protein mediating iron import (TfR1) iron <br />                                            exporter (Fpn1) rapamycin raises possibilities. First, mTOR inhibition may <br />                                            negatively regulate expression TfR1, leading reduced iron import net iron loss <br />                                            cell. The resulting deficiency activate IRP1/2 subsequent inhibition of <br />                                            Fpn1 prevent iron loss (Figure S3A). Alternatively, rapamycin primarily <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            target Fpn1 leading cellular iron accumulation decreased export. This would <br />                                            suppress IRP1/2 activity secondarily reduce TfR1 levels stop iron gain the <br />                                            import (Figure S3B). To distinguish possibilities, assessed time- <br />                                            course TfR1 Fpn1 expression 24 hours rapamycin treatment. We <br />                                            observed steady decrease TfR1 mRNA levels rapamycin, Fpn1 expression <br />                                            initially upregulated 2 4 hours, followed decline (Figure 3A). These findings <br />                                            point possibility mTOR primarily regulating TfR1 expression, the <br />                                            changes Fpn1 secondary effect (Figure S3A). Consequently, focused our <br />                                            efforts studying regulation TfR1 mTOR. <br />  <br />                                            To uncover mechanism mTOR regulates TfR1, assessed stability <br />                                            TfR1 mRNA rapamycin treatment. Incubation rapamycin-treated MEFs a <br />                                            transcriptional inhibitor actinomycin D led significant reduction TfR1 mRNA <br />                                            stability relative control group (Figure 3B), suggestive post-transcriptional <br />  <br />  <br />                                                Cell Metab. Author manuscript; available PMC 2013 November 07. <br />                             Bayeva et al.                                                                                            Page 4 <br />  <br />  <br />                                            regulation. The key known post-transcriptional regulators TfR1 IRP1/2 proteins, <br />                                            which, hypothesized, mediate mTOR-dependent changes TfR1. To determine <br />                                            IRP1/2 pathway mediates suppression TfR1 rapamycin, downregulated IRP1 <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            expression IRP2 KO MEFs using siRNA approach (IRP1/2 KD/KO MEFs), which <br />                                            resulted significant knockdown IRP1 expression (Figure 3C) reduction TfR1 <br />                                            mRNA, consistent functional inhibition IRP1/2 pathway (Figure S3C). <br />                                            However, repression TfR1 rapamycin intact IRP1/2 KD/KO MEFs <br />                                            (Figure 3D), indicating regulation TfR1 mTOR independent IRP1/2 <br />                                            pathway. <br />  <br />                               TTP functionally similar iron-regulating yeast Cth1p/Cth2p proteins <br />                                            Recent studies S. cerevisiae TZF proteins, Cth1p Cth2p, regulate cellular <br />                                            iron homeostasis binding AU-rich elements (AREs) destabilizing mRNAs of <br />                                            iron-requiring proteins salvaging iron use essential functions (Puig et al., 2005). <br />                                            Since showed IRP1/2 proteins mediate effects mTOR TfR1, we <br />                                            hypothesized TZF proteins regulate TfR1 cellular iron homeostasis in <br />                                            mammals. Three TZF proteins homology Cth1p Cth2p, TTP (ZFP36), CMG1 <br />                                            (Zfp36l1) TIS11D (Zfp36l2), identified mammals (Baou et al., 2009) and <br />                                            studied context cytokine signaling (Carrick et al., 2004). To determine whether <br />                                            proteins modulate iron homeostasis similar Cth1p/Cth2p yeast, assessed <br />                                            regulation cellular iron levels. Iron chelation DFO resulted significant and <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            dose-dependent upregulation TTP mRNA (Figure 3E) protein expression (Figure 3F). <br />                                            Treatment 2,2&#226;&#8364;&#8220;bipyridyl (2,2-BPD), lipophilic iron chelator mechanistically <br />                                            distinct DFO, induced TTP expression (Figure 3G), suggesting observed <br />                                            effect reduction cellular iron restricted DFO. Moreover, <br />                                            iron overload ferric ammonium citrate (FAC) suppressed TTP expression (Figure 3G). <br />                                            The mRNA levels TZF proteins increased DFO MEFs and <br />                                            H9c2 cells (Figure S3D,E), however, excluded subsequent studies the <br />                                            lack regulation mTOR (Figure S3F,G). Taken together, results that, similar <br />                                            Cth1p/Cth2p yeast, TTP regulated cellular iron status mammals. <br />  <br />                                            To confirm functional similarity Cth1p/Cth2p TTP, studied the <br />                                            ability TTP reduce expression ARE-containing iron-requiring proteins (ABCE1, <br />                                            Fe/S cluster protein involved ribosome biogenesis Lias, lipoic acid synthase) <br />                                            (Figure S3H). Similar yeast, iron chelation reduced expression ABCE1 Lias in <br />                                            WT MEFs (Figure 3H), did suppress mRNA levels proteins not <br />                                            require iron function (Figure S3I). Moreover, mRNA levels ABCE1 Lias <br />                                            increased TTP KO MEFs (Figure 3I S3J), ABCE1 levels reduced by <br />                                            TTP overexpression WT MEFs (Figure S3J,K), confirming inhibitory function of <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            TTP. DFO treatment TTP KO MEFs failed decrease, instead led an <br />                                            exaggerated increase expression ABCE1 Lias (Figure 3J), suggesting TTP <br />                                            critical repression iron-containing proteins iron chelation. Finally, to <br />                                            determine mammalian TTP complement Cth1p/Cth2p deletion yeast, we <br />                                            expressed WT TZF-mutant allele human TTP (C124R) (Lai et al., 1999) under <br />                                            control iron-regulated CTH2 promoter yeast cells. Similar MEFs, treatment <br />                                            Cth1&#206;&#8221;Cth2&#206;&#8221; yeast iron chelator bathophenanthroline (BPS) led increase in <br />                                            mRNA levels known Cth1p/Cth2p targets, succinate dehydrogenase subunit 4 <br />                                            (SDH4) aconitase (ACO1), transfection cells Cth2 plasmid restored <br />                                            suppression iron-containing genes iron deficiency (Figure 3K). Moreover, <br />                                            overexpression WT human TTP, C124R construct, reduced mRNA levels <br />                                            SDH4 ACO1 iron-limiting conditions, suggestive functional conservation <br />                                            yeast Cth1p/Cth2p mammalian TTP (Figure 3K). Taken together, findings <br />  <br />  <br />                                                Cell Metab. Author manuscript; available PMC 2013 November 07. <br />                             Bayeva et al.                                                                                            Page 5 <br />  <br />  <br />                                            suggest role TTP regulation cellular iron homeostasis similar that <br />                                            performed yeast Cth1p/Cth2p, suppressing expression iron-containing <br />                                            proteins potentially optimizing iron utilization low-iron states. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                               mTOR regulates TTP expression <br />                                            Next, assessed mTOR regulates expression TTP. Rapamycin treatment of <br />                                            MEFs H9c2 cells induced expression TTP mRNA protein (Figure 4A,B and <br />                                            S4A). Significant upregulation TTP mRNA observed Torin-1 treated MEFs <br />                                            H9c2 cells (Figure S4B,C). TTP levels suppressed mTOR activation TSC2 <br />                                            KO-V MEFs, rapamycin reversed effects (Figure 4C). Moreover, rapamycin <br />                                            treatment WT MEFs resulted significant decrease levels stability TTP <br />                                            targets ABCE1 Lias, consistent TTP induction (Figure S4D,E). Treatment cells <br />                                            rapamycin DFO led greater induction TTP expression agent <br />                                            (Figure S4F), suggesting additive effect. Importantly, downstream effects of <br />                                            TTP rapamycin iron regulation independent inflammatory response, as <br />                                            did detect TNF&#206;&#177; mRNA expression MEFs H9c2 cells (Figure S4G,H). Finally, <br />                                            determine regulation TZF proteins mTOR conserved between <br />                                            eukaryotic organisms, treated WT yeast strain rapamycin observed significant <br />                                            induction Cth1 Cth2 mRNA (Figure 4D), consistent observations the <br />                                            mammalian cells. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            Since mTOR cellular iron status known regulate hypoxia-inducible factor <br />                                            (HIF) signaling, assessed TTP regulation aryl hydrocarbon receptor nuclear <br />                                            translocator (ARNT) KO MEFs lack obligate binding partner HIF1&#206;&#177; HIF2&#206;&#177;, <br />                                            disrupting HIF pathway (Patel Simon, 2008). We TTP levels increased <br />                                            DFO rapamycin treatment ARNT KO MEFs (Figure 4E,F), indicating that <br />                                            observed regulation HIF-independent. Moreover, observed significant induction of <br />                                            TTP expression IRP1/2 KD/KO MEFs (Figure 4G,H), suggesting activity of <br />                                            IRP1/2 does mediate upregulation TTP expression rapamycin and <br />                                            DFO. In summary, TTP negatively regulated mTOR pathway HIF- <br />                                            IRP1/2-independent manner. <br />  <br />                               TTP associates regulates TfR1 mRNA <br />                                            Since TTP modulates cellular iron homeostasis downstream target mTOR, we <br />                                            hypothesized TTP regulate TfR1. Computational analysis 3&#226;&#8364;&#8482;UTR TfR1 <br />                                            revealed multiple putative AREs, close proximity or <br />                                            overlapped IREs (Figure S5A). Consistently, TfR1 mRNA levels be <br />                                            increased TTP KO MEFs (Figure 4I) TTP siRNA H9c2 cells (Figure S5B), <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            TTP overexpression reduced TfR1 levels MEFs (Figure 4J). Moreover, TfR1 <br />                                            mRNA significantly stabilized TTP KO MEFs presence actinomycin D <br />                                            (Figure 4K), confirming TTP regulates TfR1 expression level mRNA stability. <br />  <br />                                            To determine TTP regulates TfR1 mRNA 3&#226;&#8364;&#8482;UTR, cloned full-<span id='am-5' about='xsp:length' typeof='owl:Thing'>length</span> <br />                                            3&#226;&#8364;&#8482;UTR mouse TfR1 downstream firefly luciferase gene (TfR1-3&#226;&#8364;&#8482;UTR-Luc, Figure <br />                                            5A), used renilla luciferase construct normalize transfection efficiency. Consistent <br />                                            TTP suppression TfR1 3&#226;&#8364;&#8482;UTR, transfection TfR1-3&#226;&#8364;&#8482;UTR-Luc construct <br />                                            WT MEFs overexpressing TTP led significant reduction luminescence signal <br />                                            (Figure 5B), luminescence increased TTP KO MEFs (Fig 5C). <br />  <br />                                            Finally, assess interaction TTP TfR1 mRNA, performed RNA co- <br />                                            immunoprecipitation (RNA Co-IP) experiment using anti-TTP control IgG antibody <br />                                            bait analyzing mRNA targets TTP qRT-PCR (Table 1), described previously <br />  <br />  <br />                                                Cell Metab. Author manuscript; available PMC 2013 November 07. <br />                             Bayeva et al.                                                                                           Page 6 <br />  <br />  <br />                                            (Emmons et al., 2008). Since monoclonal antibody used studies raised against <br />                                            human TTP, pull-down experiments performed human HEK293 cells. We <br />                                            designed distinct primer sets TfR1 target regions near 3&#226;&#8364;&#8482;UTR, primer <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            sets positive controls. We observed enrichment known targets TTP <br />                                            (VEGF (Essafi-Benkhadir et al., 2007) Pitx-2 (Briata et al., 2003)) TTP antibody <br />                                            group compared IgG, enrichment observed negative <br />                                            controls tested (Table 1). TfR1 mRNA levels significantly enriched TTP group <br />                                            compared IgG control (Table 1, Figure 5D), indicative interaction TTP <br />                                            TfR1 mRNA. Taken together, results TTP induced rapamycin and <br />                                            regulates TfR1 expression posttranscriptional level. <br />  <br />                               mTOR regulates iron homeostasis TTP <br />                                            Finally, asked TTP mediates changes TfR1 expression observed with <br />                                            mTOR modulation. TTP KO MEFs incubated rapamycin, expression of <br />                                            TfR1 assessed. In TTP WT MEFs, rapamycin led expected ~50% decrease in <br />                                            TfR1 levels; however, TTP KO MEFs reduction TfR1 expression significantly <br />                                            blunted (Figure 5E). Furthermore, expression ARE-containing iron-requiring <br />                                            proteins reduced rapamycin WT MEFs, response greatly attenuated in <br />                                            TTP KO MEFs (Figure 5F). Finally, TfR1 mRNA stability reduced WT MEFs <br />                                            incubated rapamycin, TTP KO MEFs (Figure 5G). These results establish <br />                                            TTP downstream target mTOR, activity partially responsible for <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            mTOR-dependent regulation TfR1. <br />  <br />                                            While shown TTP regulates TfR1 mRNA stability, significance TfR1 <br />                                            downregulation setting iron deficiency respect IRP1/2 pathway is <br />                                            unclear. We hypothesized TTP acts &#226;&#8364;&#339;brake&#226;&#8364;? IRP1/2 prevent the <br />                                            unnecessary over-activation iron uptake cell reducing iron use TTP- <br />                                            dependent downregulation iron-containing proteins. If correct, hypothesis predicts <br />                                            exaggerated induction TfR1 iron deficiency absence TTP, higher levels <br />                                            TTP blunt TfR1 upregulation iron chelation. Consistently, the <br />                                            degree TfR1 upregulation significantly greater DFO-treated TTP KO MEFs <br />                                            compared chelated TTP WT MEFs (Figure 5H), combination DFO and <br />                                            rapamycin, additive effect TTP upregulation (Figure S4F), led to <br />                                            attenuation TfR1 induction compared DFO (Figure S5C). <br />  <br />                                            To assess functional importance TTP regulation cellular iron, measured the <br />                                            survival TTP KO MEFs iron-deficient conditions. We hypothesized TTP is <br />                                            protective low iron states, deletion result increased cell death iron <br />                                            chelation. Consistently, observed significant drop cell viability TTP KO MEFs <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            treated 250&#194;&#181;M DFO 250&#194;&#181;M 2,2-BPD 40 hrs (Figure 5I). In addition, TTP KO <br />                                            MEFs exquisitely sensitive serum deprivation (Figure S5D), main <br />                                            source iron growth medium (Kakuta et al., 1997), glutamine deprivation <br />                                            (Figure S5D), indicative tolerance TTP KO MEFs general cellar stressors. <br />                                            Supplementation TTP KO MEFs transferrin-bound iron significantly, although <br />                                            completely, reversed effects serum deprivation cell viability, effect <br />                                            viability TTP KO MEFs grown serum-replete medium (Figure S5E). These findings <br />                                            suggest TTP KO MEFs reduced cell viability deprived iron compared to <br />                                            TTP WT MEFs. <br />  <br />                                            To determine cell death iron-deficient TTP KO MEFs mediated mTOR <br />                                            pathway, pre-treated TTP KO MEFs rapamycin 6 hours, followed co- <br />                                            incubation DFO 2,2-BPD. Surprisingly, rapamycin significantly attenuated cell <br />                                            death iron chelation (Figure 5J). Analysis cell cycle progression revealed <br />  <br />                                                Cell Metab. Author manuscript; available PMC 2013 November 07. <br />                             Bayeva et al.                                                                                          Page 7 <br />  <br />  <br />                                            significantly higher baseline division rates TTP KO MEFs compared TTP WT MEFs <br />                                            (Figure S5F), defect cell cycle arrest response DFO (Figure S5G,H). On the <br />                                            hand, pre-treatment TTP KO MEFs rapamycin prior chelation DFO has <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            equally suppressed cell cycle progression TTP KO TTP WT MEFs (Figure S5G,H), <br />                                            suggesting rapamycin-dependent preservation viability TTP KO MEFs to <br />                                            suppression cell division TTP KO MEFs. <br />  <br />                                            In summary, results suggest mTOR regulates cellular iron homeostasis TfR1 <br />                                            expression TTP inhibition function negative feedback loop fine- <br />                                            tune iron deficiency response maintain cell viability low-iron states. <br />  <br />                               mTOR TTP regulate iron homeostasis vivo <br />                                            So far data suggest mTOR TTP regulate expression TfR1 iron <br />                                            homeostasis MEFs H9c2 cells. To determine pathways play role in <br />                                            regulation iron homeostasis vivo, treated c57 black WT mice 5 daily <br />                                            intraperitoneal (IP) injections rapamycin inhibit mTOR, studied iron <br />                                            regulation triple TTP- TNF&#206;&#177; receptors 1 2 knockout (TTP/TNFR1/2 KO) mice. <br />                                            While mice deletion TTP display profound inflammation primarily to <br />                                            stabilization TNF&#206;&#177; (Taylor et al., 1996), TTP/TNFR1/2 triple-KO mice no <br />                                            inflammatory <span id='am-86' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-87' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-88' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-89' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-90' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-91' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-92' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-93' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-94' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-95' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-96' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-97' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-98' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-99' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-100' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-101' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-102' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-103' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-104' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-105' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-106' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-107' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-108' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-109' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-110' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-111' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-112' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-113' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-114' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-115' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-116' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-117' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-118' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-119' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-120' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-121' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-122' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-123' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-124' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-125' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-126' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-127' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-128' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-129' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-130' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-131' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-132' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-133' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-134' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-135' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-136' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-137' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-138' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-139' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-140' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-141' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-142' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-143' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-144' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-145' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-146' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-147' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-148' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-149' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-150' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-151' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-152' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-153' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-154' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-155' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-156' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-157' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-158' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-159' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-160' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-161' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-162' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-163' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span>phenotype</span> year age (Carballo Blackshear, 2001) thus <br />                                            represent suitable model study iron regulation. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            Treatment WT mice IP rapamycin successfully inhibited mTOR signaling, as <br />                                            evidenced absence pS6 expression (Figure S6A). Similar vitro findings, <br />                                            nonheme heme iron levels increased (Figure 6A,B), expression TfR1 <br />                                            Fpn1 reduced (Figure 6C,D), hearts rapamycin-treated mice. TTP <br />                                            expression induced rapamycin mouse hearts (Figure 6D), suggesting that <br />                                            protein potentially mediate TfR1 expression vivo. Surprisingly, assessment of <br />                                            rapamycin effects hepatic iron homeostasis revealed reduced non-heme iron levels <br />                                            (Figure S6B) decrease TfR1, preservation Fpn1 expression (Figure S6C,D). <br />                                            This suggests rapamycin primarily reduces uptake iron liver, leading to <br />                                            export-dependent iron loss. Finally, rapamycin effect expression of <br />                                            systemic iron-regulatory hormone hepcidin upstream regulators, bone <br />                                            morphogenic protein 6 (BMP6) hemojuvelin (HJV) (Figure S6E). Thus, rapamycin <br />                                            appears primarily affect iron regulation cellular level vitro vivo. <br />  <br />                                            We assessed effects TTP deletion iron regulation TTP/TNFR1/2 KO and <br />                                            WT littermate control mice. Consistent vitro findings, TfR1 protein levels were <br />                                            significantly induced TTP-deficient mouse hearts (Figure 6E), corresponded an <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            increase cardiac non-heme iron content (Figure 6F) elevated levels iron storage <br />                                            protein ferritin (light heavy chains) (Figure 6G). However, reduction the <br />                                            levels Fpn1 protein TTP deletion (Figure 6G). Analysis iron homeostasis TTP- <br />                                            deficient livers revealed significant change non-heme iron content (Figure S6F), <br />                                            TfR1or ferritin light chain protein (Figure S6G), while, similar heart, Fpn1 protein <br />                                            expression suppressed. To determine suppression Fpn1 protein to <br />                                            increased expression subsequent degradation hepcidin, measured levels this <br />                                            peptide TTP-deficient mouse livers. However, consistent unaltered hepatic iron <br />                                            levels, protein content hepcidin similar TTP/TNFR1/2 KO WT mice <br />                                            (Figure S6H), suggesting different mechanism Fpn1 downregulation heart and <br />                                            liver. Taken together, data mTOR TTP regulate TfR1 iron <br />                                            homeostasis vitro vivo, providing iron-regulatory pathway likely <br />                                            complements cellular functions IRP1/2. <br />  <br />  <br />  <br />                                                Cell Metab. Author manuscript; available PMC 2013 November 07. <br />                             Bayeva et al.                                                                                            Page 8 <br />  <br />  <br />                               DISCUSSION <br />                                            Iron essential catalysis reactions appears intimate link <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            iron energy metabolism. Short-term iron deficiency known promote <br />                                            insulin sensitivity, iron overload lead glucose intolerance (Dongiovanni et al., <br />                                            2008; Liu et al., 2009). Iron accumulation linked non-alcoholic fatty liver disease, <br />                                            cause alteration function adipocytes ability oxidize glucose <br />                                            (Dongiovanni et al., 2011). On cellular level, circumstantial evidence points a <br />                                            cross-talk energy sensing iron regulatory pathways, exemplified study <br />                                            Galvez et. al. identifies mTOR positive regulator transferrin-bound iron <br />                                            uptake (Galvez et al., 2007), iron deficiency shown inhibit mTOR signaling <br />                                            (Ndong et al., 2009; Ohyashiki et al., 2009). However, direct systematic studies of <br />                                            mTOR iron regulation lacking. Here, pathway links mTOR, a <br />                                            major metabolic hub cell, regulation cellular iron uptake flux the <br />                                            modulation TfR1 expression. The mechanism observed changes partially <br />                                            mediated TZF protein TTP, induced rapamycin, interacts TfR1 <br />                                            mRNA leads degradation (Figure 6H). Moreover, provide evidence <br />                                            TTP functions mammals similar yeast Cth1p/Cth2p regulating <br />                                            cellular iron reduction levels iron-containing proteins preservation of <br />                                            cell viability iron deficiency. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            While possible vitro changes cellular iron content mTOR modulation can <br />                                            solely explained differential rates cellular division &#226;&#8364;&#339;iron-dilution&#226;&#8364;? effect, the <br />                                            increased iron levels rapamycin-treated terminally-differentiated mouse hearts argue <br />                                            possibility. Moreover, repressive effects rapamycin genes involved in <br />                                            cellular iron regulation specific pathway global transcriptional <br />                                            inhibition, levels iron-independent genes unaltered even <br />                                            increased rapamycin treatment. The magnitude change iron levels mTOR <br />                                            modulation modest, suggesting mTOR fine-tune cellular iron utilization match <br />                                            metabolic requirements cell. Alternatively, modest change iron mTOR <br />                                            inhibition agreement hypothesis TTP involved iron conservation <br />                                            response. While IRP1/2 activation enhances cellular iron uptake reduces export leading <br />                                            iron accumulation, TTP primarily affects distribution iron molecules already <br />                                            present cell large induction iron import storage. The exact role TTP <br />                                            regulation iron homeostasis various environmental conditions remains be <br />                                            determined; however, data highlight importance pathway low-iron states, <br />                                            evidenced severe loss cell viability iron deficiency TTP knockout. <br />  <br />                                            The fact TTP reduces TfR1 mRNA levels stability surprising. We TTP <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            strongly induced low iron levels different cell lines mouse hearts, also <br />                                            mechanistically distinct chelators. Thus, appears counterintuitive TTP signals to <br />                                            degrade TfR1 message IRP1/2 concurrently stabilize mRNA. A similar situation <br />                                            described yeast cells Aft1p (the yeast homolog IRP1/2) activates the <br />                                            transcription FIT1 FIT2 genes involved iron uptake, Cth2p promotes their <br />                                            degradation response iron deficiency (Puig et al., 2005). We hypothesize parallel <br />                                            activation pathways serves fine-tune TfR1 levels based severity iron <br />                                            deficiency degree reduction cellular iron utilization TTP. As levels of <br />                                            iron-containing proteins decrease iron available, need additional <br />                                            import iron down, corresponding reduction TfR1 levels. In words, <br />                                            TTP act &#226;&#8364;&#339;brake&#226;&#8364;? IRP1/2 response better match rate iron import <br />                                            actual needs cell spare exogenous iron use tissues. The <br />                                            relative contribution TTP IRP1/2 pathways iron deficiency response remains be <br />                                            determined; however, significant sequence overlap AREs IREs, binding <br />  <br />  <br />                                                Cell Metab. Author manuscript; available PMC 2013 November 07. <br />                             Bayeva et al.                                                                                          Page 9 <br />  <br />  <br />                                            sites TTP IRP1/2, respectively, suggests possibility steric hindrance effects. <br />                                            Moreover, rapid activation IRP1/2 slower transcriptional induction TTP by <br />                                            iron deficiency provide additional degree regulation, IRP1/2 serving <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            rapid response aimed correcting iron deficiency enhancing iron uptake. If <br />                                            unsuccessful, TTP-mediated iron-conservation program subsequently induced, <br />                                            allowing cells survive chronic iron deficiency. <br />  <br />                                            In addition TTP, data suggest existence another, unidentified, pathway <br />                                            mediating mTOR-dependent changes iron homeostasis. First, observed a <br />                                            significant attenuation, complete reversal rapamycin effects TTP KO MEFs. <br />                                            Second, rapamycin administration caused rapid progressive reduction TfR1 <br />                                            mRNA levels, reaching significance hours treatment (n=18). Since induction <br />                                            TTP rapamycin represents later-stage response, acute mechanism, as <br />                                            phosphorylation event microRNA processing, explain findings. Moreover, is <br />                                            presently unclear TTP expression regulated mTOR. We induction of <br />                                            TTP rapamycin unaltered MEFs defective HIF IRP1/2 signaling, suggesting <br />                                            pathways involved mTOR-dependent regulation TTP. It also <br />                                            unlikely rapamycin regulates TTP levels indirectly increase cellular iron <br />                                            levels, rapamycin iron chelation DFO additive, an <br />                                            opposing, effect TTP induction. Thus, pathways downstream mTOR play a <br />                                            role regulation TTP cellular iron homeostasis. Moreover, data not <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            exclude possibility independent roles mTOR TTP pathways regulation of <br />                                            TfR1 iron homeostasis. Extensive characterization molecular networks, <br />                                            environmental signals downstream effectors pathways shed light their <br />                                            biological role iron regulation. <br />  <br />                                            In summary, identified mTOR TTP new players cellular iron homeostasis that <br />                                            regulate mRNA stability TfR1 iron-containing genes. Moreover, described the <br />                                            existence Cth1p/Cth2p-like pathway mammalian cells represent an <br />                                            important iron-deficiency response mechanism functions parallel well- <br />                                            established IRP1/2 regulatory system. <br />  <br />                               EXPREIMENTAL PROCEDURES <br />                               Cell culture reagents <br />                                            MEFs grown complete DMEM medium (Cellgro, VA) supplemented 10% FBS <br />                                            (Invitrogen, CA) 1% penicillin-streptomycin (P/S). For glutamine-deprivation <br />                                            experiments Cellgro DMEM L-glutamine (Cat. # 15-013-CV) used. Each the <br />                                            genetically modified MEF lines compared matched WT MEFs obtained a <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            littermate control mouse. TSC2 KO-V TSC2 KO-TSC2 MEFs described <br />                                            previously (Zhang et al., 2003). TTP KO (line 66) TTP WT (line 67) MEFs were <br />                                            derived littermate E14.5 embryos described (Taylor et al., 1996). ARNT KO MEFs <br />                                            generous gift Dr. Celeste Simon (Maltepe et al., 1997). IRP1 KO IRP2 KO <br />                                            MEFs kindly provided Dr. Tracey A. Rouault. H9c2 cardiac myoblasts were <br />                                            purchased ATCC kept complete DMEM medium (ATCC, VA) 10% FBS <br />                                            1% P/S. H9c2 MEF cells treated 20nM rapamycin (LC Labs, MA) 24 <br />                                            48 hours, 150&#194;&#181;M DFO 200&#194;&#181;M 2,2-BPD 16&#226;&#8364;&#8220;24 hours unless specifically noted, and <br />                                            50&#194;&#181;g/ml FAC 16 hrs (Sigma-Aldrich, USA). <br />  <br />  <br />  <br />  <br />                                               Cell Metab. Author manuscript; available PMC 2013 November 07. <br />                             Bayeva et al.                                                                                         Page 10 <br />  <br />  <br />                               siRNA treatment <br />                                              H9c2 cells transfected siRNA using DharmaFect (Thermo Scientific, CO) reagent <br />                                              according manufacturer&#226;&#8364;&#8482;s protocol. Rat TSC2 siGENOME siRNA (Thermo Scientific, <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                              CO) rat TTP FlexiTube siRNA (Quiagen, CA) used. <br />  <br />                               Quantitiative RT-PCR <br />                                              RNA isolated RNA STAT-60 (TEL-TEST, Inc, TX), reverse-transcribed a <br />                                              Random Hexamer (Applied Biosystems, CA), amplified 7500 Fast Real-Time PCR <br />                                              SYBR Green PCR Master Mix (Applied Biosystems, CA). Primers were <br />                                              designed using Primer3 (v. 0.4.0) software target sequences spanning exon-intron-exon <br />                                              boundary. mRNA levels calculated comparative threshold cycle method and <br />                                              normalized &#206;&#178;-actin and/or HPRT gene. <br />  <br />                               Western blot <br />                                              Fifteen-30 &#194;&#181;g protein resolved SDS-PAGE gels transferred nitrocellulose <br />                                              membranes (Invitrogen, CA) probed antibodies pS6 (Cell <br />                                              Signaling, MA), TfR1 (Invitrogen, CA), Slc40A1 (Fpn1, Novus Biologicals, CO), TTP (Cao <br />                                              et al., 2004) Tubulin (Abcam, MA). HRP-conjugated donkey anti-rabbit donkey <br />                                              anti-mouse used secondary antibodies (Santa Cruz, CA) visualized Pierce <br />                                              SuperSignal Chemiluminescent Substrates. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                               Plasmid transfections <br />                                              Plasmids transfected MEFs using Lipofectamine reagent (Invitrogen, CA) in <br />                                              OptiMEM (Cellgro, VA) hours, followed incubation complete, antibiotic-free <br />                                              medium 20 hours. <br />  <br />                               Non-heme heme iron assays <br />                                              Non-heme iron measured described (Rebouche et al., 2004). Briefly, equal amounts <br />                                              protein mixed protein precipitation solution (1:1 1N HCl 10% <br />                                              trichloroacetic acid) heated 95&#194;&#176;C 1h release iron. Precipitated protein was <br />                                              removed centrifugation 4&#194;&#176;C 16,000 &#195;&#8212; g 10 minutes, supernatant was <br />                                              mixed equal volume chromogen solution (0.5mM ferrozine, 1.5M sodium <br />                                              acetate, 0.1% (v/v) thioglycolic acid) absorbance measured Spectra Max Plus <br />                                              microplate reader 562 nm. Heme quantified described (Ward et al., 1984). Briefly, <br />                                              equal amounts protein mixed 2M oxalic acid, heated 95&#194;&#176;C 30 minutes to <br />                                              release iron heme generate protoporphyrin IX. Samples centrifuged for <br />                                              10 min 1,000 &#195;&#8212; g 4&#194;&#176;C remove debris, fluorescence supernatant was <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                              assessed 405nm / 600nm Spectra Max Gemini fluorescence microplate reader. <br />  <br />                               55Fe    uptake studies <br />                                              55Fe  (Perkin-Elmer, MA) conjugated nitriloacetic acid (NTA, Sigma-Aldrich, USA) <br />                                              dissolved final concentration 100&#226;&#8364;&#8220;300nM complete, serum-containing <br />                                              medium 24 hours prior beginning experiments. MEFs H9c2 incubated <br />                                              1 hour 24 hours 55Fe-containing complete medium, washed 3 times ice- <br />                                              cold 500mM BPS PBS remove membrane-associated 55Fe lysed 1% <br />                                              Triton-X100 TBS. The radioactivity sample determined Beckman <br />                                              scintillation counter normalized protein content sample. <br />  <br />  <br />  <br />  <br />                                                 Cell Metab. Author manuscript; available PMC 2013 November 07. <br />                             Bayeva et al.                                                                                         Page 11 <br />  <br />  <br />                               mRNA stability assay <br />                                            MEFs incubated complete medium supplemented 5&#194;&#181;M actinomycin D <br />                                            (Sigma-Aldrich, USA) 3&#226;&#8364;&#8220;6 hours. No drop cell viability observed end of <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            treatment. RNA collected mRNA levels analyzed qRT-PCR as <br />                                            described above. <br />  <br />                               RNA-CoIP <br />                                            The protocol adapted Emmons et. al (Emmons et al., 2008) following <br />                                            modifications. HEK-293 cells resuspended Buffer A (10mM Tris&#226;&#8364;&#8220;HCl pH 7.6, 1mM <br />                                            KAc, 1.5mM MgAc, 2mM DTT, 10&#194;&#181;l/ml Protease Arrest inhibitors), lysed using Power <br />                                            Gen 500 homogenizer (Fisher Scientific, PA), followed centrifugation 12,000 &#195;&#8212; g for <br />                                            10 min 4&#194;&#176;C remove debris. Protein G Sepharose Fast Flow beads (Sigma-Aldrich, <br />                                            USA) incubated human TTP (kindly provided Dr. William Rigby, Dartmouth <br />                                            University) IgG antibody IP Buffer (10mM Tris-HCl pH 7.6, 1.5mM MgCl2, <br />                                            100mM NaCl, 0.5% Triton X-100, 10&#194;&#181;l/ml Protease Arrest inhibitors) 4&#194;&#176;C with <br />                                            continuous rotation 4 hours. Beads washed 6 times cold IP buffer and <br />                                            incubated HEK-293 lysate 4&#194;&#176;C continuous rotation 2 hours. RNA was <br />                                            collected equal amounts amplified qRT-PCR. Expression gene was <br />                                            normalized 18S data expressed fold enrichment IgG control. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                               Luciferase Assay <br />                                            Luciferase assay TfR1-3&#226;&#8364;&#8482;UTR-Luc various ARE-deletion constructs performed <br />                                            using Dual Glo Luciferase Assay (Promega) according manufacturer&#226;&#8364;&#8482;s <br />                                            protocol. 3&#226;&#8364;&#8482; UTR TfR1 cloned pMIR-report vector containing gene for <br />                                            firefly luciferase (Ambion) confirmed sequencing. The luminescence quantified <br />                                            Berthold Technologies Luminometer (Germany) Dual-Glo&#194;&#174; Stop &amp; Glo&#194;&#174; <br />                                            reagent added quench firefly luminescence provide substrate renilla <br />                                            luminescence used normalize transfection efficiency. <br />  <br />                               Cell death studies <br />                                            Cell death assessed labeling PI (Sigma-Aldrich, USA) and/or Alexa Fluor&#194;&#174; <br />                                            350-conjugated Annexin V (Molecular Probes, NY), analyzed flow cytometry a <br />                                            FacsCanto flow cytometer (BD Bioscience). For cell-cycle studies, cells incubated <br />                                            rapamycin 6 hours co-incubated DFO rapamycin 10-hours prior to <br />                                            collection. Cells collected trypsinization, washed, fixed 70% ethanol at <br />                                            &#226;&#710;&#8217;20&#194;&#176;C hours, followed incubation PI staining solution (50&#194;&#181;g/mL PI, <br />                                            0.2mg/ml RNAse A, 0.1% Triton X-100 PBS) 37&#194;&#176;C 20 minutes. Cell cycle was <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            analyzed flow cytometry FlowJo 7.6 software. <br />  <br />                               Mouse studies <br />                                            Wild-type C57BL/6 females purchased Jackson labs treated 5 daily <br />                                            intraperitoneal injections rapamycin 10mg/kg DMSO. Mice anesthetized <br />                                            250mg/kg dose freshly-prepared Tribromoethanol (Avertin) harvested <br />                                            organs flash-frozen liquid nitrogen. The animal studies conducted in <br />                                            accordance Northwestern University animal care guidelines. <br />  <br />                               Yeast studies <br />                                            Yeast cth1&#206;&#8221;cth2&#206;&#8221; cells transformed pRS416 vector expressing CTH2, TTP or <br />                                            TTP-C124R control CTH2 promoter region grown synthetic media <br />                                            containing 300&#194;&#181;M iron (+ Fe) 100&#194;&#181;M Fe2+-specific chelator bathophenanthroline <br />                                            disulfonic acid (&#226;&#710;&#8217; Fe), RNA extracted analyzed RNA blotting previously <br />  <br />                                               Cell Metab. Author manuscript; available PMC 2013 November 07. <br />                             Bayeva et al.                                                                                                            Page 12 <br />  <br />  <br />                                            described (Puig et al., 2005). Actin (ACT1) mRNA levels used loading control. <br />                                            Wild-type yeast cells exponential phase growth treated 1&#194;&#181;g/mL of <br />                                            rapamycin 16 hours, following mRNA collected expression Cth1/2 <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            genes analyzed qRT-PCR. <br />  <br />                               Statistical analysis <br />                                            Data expressed mean &#194;&#177; SEM. Statistical significance assessed unpaired <br />                                            Student t test; P value 0.05 considered statistically significant. <br />  <br />                               Supplementary Material <br />                                            Refer Web version PubMed Central supplementary material. <br />  <br />  <br />                               Acknowledgments <br />                                            We thank Dr. Seth A. Brooks help TTP RNA-CoIP experiments, Drs. Sarah Rice, Navdeep Chandel and <br />                                            Elizabeth Leibold critical review manuscript, Drs. William F.C. Rigby, M. Celeste Simon and <br />                                            Tracey A. Rouault generous gifts human TTP antibody, ARNT KO MEFs, IRP1 2 KO <br />                                            MEFs respectively. This work supported Northwestern University Flow Cytometry Facility a <br />                                            Cancer Center Support Grant (NCI CA060553). M.B. H.A. designed research. M.B., A.K. S.P. <br />                                            performed experiments data analysis. P.J.B S.P. provided tools reagents. M.B. wrote the <br />                                            manuscript, authors commented on. H.A. supervised project. M.B. supported American <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            Heart Association 10PRE4430021. H.A. supported NIH grants K02 HL107448 R01 HL087149. <br />  <br />  <br />                               REFERENCES <br />                                            Aisen P, Enns C, Wessling-Resnick M. Chemistry biology eukaryotic iron metabolism. Int J <br />                                              Biochem Cell Biol. 2001; 33:940&#226;&#8364;&#8220;959. [PubMed: 11470229] <br />                                            Altamura S, Muckenthaler MU. Iron toxicity diseases aging: Alzheimer&apos;s disease, Parkinson&apos;s <br />                                              disease atherosclerosis. J Alzheimers Dis. 2009; 16:879&#226;&#8364;&#8220;895. [PubMed: 19387120] <br />                                            Anderson GJ, Vulpe CD. Mammalian iron transport. Cell Mol Life Sci. 2009; 66:3241&#226;&#8364;&#8220;3261. <br />                                              [PubMed: 19484405] <br />                                            Arredondo M, Nunez MT. Iron copper metabolism. Mol Aspects Med. 2005; 26:313&#226;&#8364;&#8220;327. <br />                                              [PubMed: 16112186] <br />                                            Baou M, Jewell A, Murphy JJ. TIS11 family proteins roles posttranscriptional gene <br />                                              regulation. J Biomed Biotechnol. 2009; 2009:634520. [PubMed: 19672455] <br />                                            Briata P, Ilengo C, Corte G, Moroni C, Rosenfeld MG, Chen CY, Gherzi R. The Wnt/beta-catenin-- <br />                                              &gt;Pitx2 pathway controls turnover Pitx2 unstable mRNAs. Mol Cell. 2003; <br />                                              12:1201&#226;&#8364;&#8220;1211. [PubMed: 14636578] <br />                                            Cao H, Tuttle JS, Blackshear PJ. Immunological characterization tristetraprolin low abundance, <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                              inducible, stable cytosolic protein. J Biol Chem. 2004; 279:21489&#226;&#8364;&#8220;21499. [PubMed: 15010466] <br />                                            Carballo E, Blackshear PJ. Roles tumor necrosis factor-alpha receptor subtypes pathogenesis <br />                                              tristetraprolin-deficiency syndrome. Blood. 2001; 98:2389&#226;&#8364;&#8220;2395. [PubMed: 11588035] <br />                                            Carrick DM, Lai WS, Blackshear PJ. The tandem CCCH zinc finger protein tristetraprolin its <br />                                              relevance cytokine mRNA turnover arthritis. Arthritis Res Ther. 2004; 6:248&#226;&#8364;&#8220;264. [PubMed: <br />                                              15535838] <br />                                            Dongiovanni P, Fracanzani AL, Fargion S, Valenti L. Iron fatty liver metabolic <br />                                                syndrome: promising therapeutic target. J Hepatol. 2011; 55:920&#226;&#8364;&#8220;932. [PubMed: 21718726] <br />                                            Dongiovanni P, Valenti L, Ludovica Fracanzani A, Gatti S, Cairo G, Fargion S. Iron depletion by <br />                                                deferoxamine up-regulates glucose uptake insulin signaling hepatoma cells rat liver. <br />                                                Am J Pathol. 2008; 172:738&#226;&#8364;&#8220;747. [PubMed: 18245813] <br />                                            Dunlop EA, Tee AR. Mammalian target rapamycin complex 1: signalling inputs, substrates and <br />                                                feedback mechanisms. Cell Signal. 2009; 21:827&#226;&#8364;&#8220;835. [PubMed: 19166929] <br />  <br />  <br />  <br />  <br />                                                Cell Metab. Author manuscript; available PMC 2013 November 07. <br />                             Bayeva et al.                                                                                                   Page 13 <br />  <br />  <br />                                            Emmons J, Townley-Tilson WH, Deleault KM, Skinner SJ, Gross RH, Whitfield ML, Brooks SA. <br />                                                Identification TTP mRNA targets human dendritic cells reveals TTP critical regulator of <br />                                                dendritic cell maturation. RNA. 2008; 14:888&#226;&#8364;&#8220;902. [PubMed: 18367721] <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            Essafi-Benkhadir K, Onesto C, Stebe E, Moroni C, Pages G. Tristetraprolin inhibits Ras-dependent <br />                                                tumor vascularization inducing vascular endothelial growth factor mRNA degradation. Mol <br />                                                Biol Cell. 2007; 18:4648&#226;&#8364;&#8220;4658. [PubMed: 17855506] <br />                                            Galvez T, Teruel MN, Heo WD, Jones JT, Kim ML, Liou J, Myers JW, Meyer T. siRNA screen the <br />                                                human signaling proteome identifies PtdIns(3,4,5)P3-mTOR signaling pathway primary <br />                                                regulator transferrin uptake. Genome Biol. 2007; 8:R142. [PubMed: 17640392] <br />                                            Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two tango: regulation Mammalian iron <br />                                                metabolism. Cell. 2010; 142:24&#226;&#8364;&#8220;38. [PubMed: 20603012] <br />                                            Howell JJ, Manning BD. mTOR couples cellular <span id='am-3' about='Thesaurus:Nutrient' typeof='owl:Thing'>nutrient</span> sensing organismal metabolic <br />                                                homeostasis. Trends Endocrinol Metab. 2011; 22:94&#226;&#8364;&#8220;102. [PubMed: 21269838] <br />                                            Kakuta K, Orino K, Yamamoto S, Watanabe K. High levels ferritin iron fetal bovine <br />                                                serum. Comp Biochem Physiol A Physiol. 1997; 118:165&#226;&#8364;&#8220;169. [PubMed: 9243818] <br />                                            Kim MJ, Mayr M, Pechula M, Steiger J, Dickenmann M. Marked erythrocyte microcytosis under <br />                                                primary immunosuppression sirolimus. Transpl Int. 2006; 19:12&#226;&#8364;&#8220;18. [PubMed: 16359372] <br />                                            Lai WS, Carballo E, Strum JR, Kennington EA, Phillips RS, Blackshear PJ. Evidence that <br />                                                tristetraprolin binds AU-rich elements promotes deadenylation destabilization of <br />                                                tumor necrosis factor alpha mRNA. Mol Cell Biol. 1999; 19:4311&#226;&#8364;&#8220;4323. [PubMed: 10330172] <br />                                            Liu Q, Sun L, Tan Y, Wang G, Lin X, Cai L. Role iron deficiency overload pathogenesis <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                diabetes diabetic complications. Curr Med Chem. 2009; 16:113&#226;&#8364;&#8220;129. [PubMed: 19149565] <br />                                            Maiorano A, Stallone G, Schena A, Infante B, Pontrelli P, Schena FP, Grandaliano G. Sirolimus <br />                                                interferes iron homeostasis renal transplant recipients. Transplantation. 2006; 82:908&#226;&#8364;&#8220;912. <br />                                                [PubMed: 17038905] <br />                                            Maltepe E, Schmidt JV, Baunoch D, Bradfield CA, Simon MC. Abnormal angiogenesis responses <br />                                                glucose oxygen deprivation mice lacking protein ARNT. Nature. 1997; 386:403&#226;&#8364;&#8220;407. <br />                                                [PubMed: 9121557] <br />                                            Ndong M, Kazami M, Suzuki T, Uehara M, Katsumata S, Inoue H, Kobayashi K, Tadokoro T, Suzuki <br />                                                K, Yamamoto Y. Iron deficiency down-regulates Akt/TSC1-TSC2/mammalian Target of <br />                                                Rapamycin signaling pathway rats COS-1 cells. Nutr Res. 2009; 29:640&#226;&#8364;&#8220;647. [PubMed: <br />                                                19854379] <br />                                            Ohyashiki JH, Kobayashi C, Hamamura R, Okabe S, Tauchi T, Ohyashiki K. The oral iron chelator <br />                                                deferasirox represses signaling mTOR myeloid leukemia cells enhancing <br />                                                expression REDD1. Cancer Sci. 2009; 100:970&#226;&#8364;&#8220;977. [PubMed: 19298223] <br />                                            Patel SA, Simon MC. Biology hypoxia-inducible factor-2alpha development disease. Cell <br />                                                Death Differ. 2008; 15:628&#226;&#8364;&#8220;634. [PubMed: 18259197] <br />                                            Pedro-Segura E, Vergara SV, Rodriguez-Navarro S, Parker R, Thiele DJ, Puig S. The Cth2 ARE- <br />                                                binding protein recruits Dhh1 helicase promote decay succinate dehydrogenase SDH4 <br />                                                mRNA response iron deficiency. J Biol Chem. 2008; 283:28527&#226;&#8364;&#8220;28535. [PubMed: <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                18715869] <br />                                            Puig S, Askeland E, Thiele DJ. Coordinated remodeling cellular metabolism iron deficiency <br />                                                targeted mRNA degradation. Cell. 2005; 120:99&#226;&#8364;&#8220;110. [PubMed: 15652485] <br />                                            Puig S, Vergara SV, Thiele DJ. Cooperation mRNA-binding proteins drives metabolic <br />                                                adaptation iron deficiency. Cell Metab. 2008; 7:555&#226;&#8364;&#8220;564. [PubMed: 18522836] <br />                                            Rebouche CJ, Wilcox CL, Widness JA. Microanalysis non-heme iron animal tissues. J Biochem <br />                                                Biophys Methods. 2004; 58:239&#226;&#8364;&#8220;251. [PubMed: 15026210] <br />                                            Rouault TA. The role iron regulatory proteins mammalian iron homeostasis disease. Nat <br />                                                Chem Biol. 2006; 2:406&#226;&#8364;&#8220;414. [PubMed: 16850017] <br />                                            Sengupta S, Peterson TR, Sabatini DM. Regulation mTOR complex 1 pathway nutrients, <br />                                                growth factors, stress. Mol Cell. 2010; 40:310&#226;&#8364;&#8220;322. [PubMed: 20965424] <br />                                            Sofroniadou S, Kassimatis T, Goldsmith D. Anaemia, microcytosis sirolimus--is iron missing <br />                                                link? Nephrol Dial Transplant. 2010; 25:1667&#226;&#8364;&#8220;1675. [PubMed: 20054028] <br />  <br />  <br />  <br />                                                Cell Metab. Author manuscript; available PMC 2013 November 07. <br />                             Bayeva et al.                                                                                                Page 14 <br />  <br />  <br />                                            Soliman GA. The mammalian target rapamycin signaling network gene regulation. Curr Opin <br />                                                Lipidol. 2005; 16:317&#226;&#8364;&#8220;323. [PubMed: 15891393] <br />                                            Taylor GA, Carballo E, Lee DM, Lai WS, Thompson MJ, Patel DD, Schenkman DI, Gilkeson GS, <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                Broxmeyer HE, Haynes BF, et al. A pathogenetic role TNF alpha syndrome cachexia, <br />                                                arthritis, autoimmunity resulting tristetraprolin (TTP) deficiency. Immunity. 1996; <br />                                                4:445&#226;&#8364;&#8220;454. [PubMed: 8630730] <br />                                            Torti SV, Torti FM. Ironing cancer. Cancer Res. 2011; 71:1511&#226;&#8364;&#8220;1514. [PubMed: 21363917] <br />                                            Wang J, Pantopoulos K. Regulation cellular iron metabolism. Biochem J. 2011; 434:365&#226;&#8364;&#8220;381. <br />                                                [PubMed: 21348856] <br />                                            Ward JH, Jordan I, Kushner JP, Kaplan J. Heme regulation HeLa cell transferrin receptor number. J <br />                                                Biol Chem. 1984; 259:13235&#226;&#8364;&#8220;13240. [PubMed: 6092369] <br />                                            Weinberg ED. The hazards iron loading. Metallomics. 2010; 2:732&#226;&#8364;&#8220;740. [PubMed: 21072364] <br />                                            WHO. Worldwide prevalence anaemia 1993&#226;&#8364;&#8220;2005. Geneva, Switzerland: WHO Press; 2008. <br />                                            Zhang H, Cicchetti G, Onda H, Koon HB, Asrican K, Bajraszewski N, Vazquez F, Carpenter CL, <br />                                                Kwiatkowski DJ. Loss Tsc1/Tsc2 activates mTOR disrupts PI3K-Akt signaling through <br />                                                downregulation PDGFR. J Clin Invest. 2003; 112:1223&#226;&#8364;&#8220;1233. [PubMed: 14561707] <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                Cell Metab. Author manuscript; available PMC 2013 November 07. <br />                             Bayeva et al.                                                                                      Page 15 <br />  <br />  <br />                                                                                  HIGHLIGHTS <br />                                            &#226;&#8364;&#162;    mTOR regulates iron homeostasis altering expression iron transporters <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            &#226;&#8364;&#162;    TTP regulates iron homeostasis, similar yeast Cth1p/2p <br />                                            &#226;&#8364;&#162;    mTOR regulates TfR1 iron homeostasis TTP <br />                                            &#226;&#8364;&#162;    TfR1 mRNA target TTP <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            Cell Metab. Author manuscript; available PMC 2013 November 07. <br />                             Bayeva et al.                                                                                        Page 16 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            Figure 1. mTOR regulates cellular iron content uptake <br />                                            (A) mTOR modulation MEFs (left) H9c2 (right) cells assessed Western blot of <br />                                            phosphorylated S6 protein. Densitometry analysis shown Western blot (n=3). <br />                                            TSC2 protein levels (right) TSC2 KO-V TSC2 KO-TSC2 MEFs. (B) Non-heme iron <br />                                            content WT MEFs treated 20nM rapamycin 48 hrs normalized protein <br />                                            concentration (n=12). All subsequent experiments carried 20nM rapamycin <br />                                            treatment 48 hrs mammalian cell lines, unless noted otherwise. (C) Non-heme iron <br />                                            content TSC2 KO-V TSC2 KO-TSC2 MEFs rapamycin treatment <br />                                            (n=6&#226;&#8364;&#8220;12). (D) Radioactive iron uptake 1 hour WT MEFs rapamycin vehicle <br />  <br />  <br />                                                Cell Metab. Author manuscript; available PMC 2013 November 07. <br />                             Bayeva et al.                                                                                    Page 17 <br />  <br />  <br />                                            control treatment (n=12). (E) Radioactive iron uptake 1 hour TSC2 KO-V TSC2 <br />                                            KO-TSC2 MEFs rapamycin (n=6&#226;&#8364;&#8220;12). (F) Cellular content 55Fe WT <br />                                            MEFs treated rapamycin vehicle control following 24-hour incubation with <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            radioactive iron (n=12). (G) Cellular content 55Fe TSC2 KO-V TSC2 KO-TSC2 <br />                                            MEFs rapamycin following 24-hour incubation radioactive iron <br />                                            (n=6). Data presented mean &#194;&#177; SEM. * p&lt;0.05 vs. control, # p&lt;0.05 vs. TSC2 KO-V <br />                                            MEFs. See Figure S1. <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                               Cell Metab. Author manuscript; available PMC 2013 November 07. <br />                             Bayeva et al.                                                                                      Page 18 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            Figure 2. mTOR regulates expression iron transporters <br />                                            Protein levels TfR1 WT MEFs (A) Fpn1 mouse hearts (B) following rapamycin <br />                                            treatment. Densitometry analyses presented Western blots. (C) mRNA levels <br />                                            iron transporters, TfR1 Fpn1, determined qRT-PCR, WT MEFs or <br />                                            rapamycin treatment (n=6&#226;&#8364;&#8220;12). (D) mRNA levels iron transporters TSC2 KO- <br />                                            V TSC2 KO-TSC2 MEFs rapamycin treatment (n=6&#226;&#8364;&#8220;12). (E) mRNA <br />                                            levels genes unrelated iron homeostasis WT MEFs treated rapamycin vehicle <br />                                            control (n=6). Data presented mean &#194;&#177; SEM. * p&lt;0.05 vs. control, # p&lt;0.05 vs. TSC2 <br />                                            KO-V MEFs. See Figure S2. <br />  <br />  <br />                                                Cell Metab. Author manuscript; available PMC 2013 November 07. <br />                             Bayeva et al.                                                                                       Page 19 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            Figure 3. TTP functionally similar yeast Cth1p/2p <br />                                            (A) Time-course TfR1 Fpn1 mRNA regulation rapamycin WT MEFs 24 <br />                                            hrs (n=12&#226;&#8364;&#8220;18). (B) TfR1 mRNA stability WT MEFs rapamycin pre- <br />                                            treatment assessed qRT-PCR incubation transcriptional inhibitor <br />                                            actinomycin D (act D), normalized TfR1 mRNA levels time point zero respective <br />                                            group (n=3). (C) IRP1 mRNA levels IRP2 KO MEFs following treatment IRP1 <br />                                            siRNA (n=6). (D) TfR1 mRNA levels IRP1/2 KD/KO MEFs following rapamycin <br />                                            treatment (n=6). TTP mRNA (E) TTP protein (F) levels WT MEFs DFO <br />                                            treatment 16 hours (n=3&#226;&#8364;&#8220;6). Densitometry analysis presented Western blot. <br />  <br />  <br />                                                Cell Metab. Author manuscript; available PMC 2013 November 07. <br />                             Bayeva et al.                                                                                       Page 20 <br />  <br />  <br />                                            (G) TTP mRNA levels H9c2 cells 16-hour incubation 2,2-BPD FAC iron <br />                                            chelation overload, respectively (n=6). (H) mRNA levels iron-containing proteins in <br />                                            WT MEFs treated 150&#194;&#181;M DFO 16 hours (n=6). Unless noted otherwise, all <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            subsequent studies performed using protocol iron chelation DFO. (I) <br />                                            mRNA levels iron-containing proteins TTP WT KO MEFs (n=12&#226;&#8364;&#8220;18). (J) mRNA <br />                                            levels iron-containing proteins TTP KO WT MEFs presence absence of <br />                                            DFO (n=6&#226;&#8364;&#8220;12). (K) mRNA levels iron-containing Cth2p targets cth1&#206;&#8221;cth2&#206;&#8221; yeast <br />                                            ectopic expression human wild-type TZF mutant TTP. Data presented as <br />                                            mean &#194;&#177; SEM. * p&lt;0.05 vs. control, # p&lt;0.05 vs. control 180 minutes. See Figure S3. <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                               Cell Metab. Author manuscript; available PMC 2013 November 07. <br />                             Bayeva et al.                                                                                  Page 21 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            Figure 4. mTOR regulates TTP expression <br />                                            TTP mRNA (A) TTP protein (B) levels WT MEFs treated rapamycin (n=6&#226;&#8364;&#8220;8). <br />                                            (C) TTP mRNA levels TSC2 KO-V TSC2 KO-TSC2 MEFs without <br />                                            rapamycin treatment (n=6&#226;&#8364;&#8220;12). (D) Cth1 Cth2 mRNA levels WT yeast cells treated <br />                                            1&#194;&#181;g/mL rapamycin 24 hours (n=6). mRNA levels TTP ARNT KO MEFs <br />                                            treated rapamycin (E) DFO (F) (n=15). TTP mRNA levels IRP1/2 KD/KO MEFs <br />                                            treated rapamycin (G) DFO (H) (n=6). (I) TfR1 mRNA levels TTP KO and <br />                                            control MEFs (n=15). (J) TfR1 mRNA levels WT MEFs transfected TTP- GFP- <br />                                            containing (control) vectors (n=6). (K) TfR1 mRNA stability TTP WT KO MEFs <br />  <br />  <br />                                               Cell Metab. Author manuscript; available PMC 2013 November 07. <br />                             Bayeva et al.                                                                                         Page 22 <br />  <br />  <br />                                            treated transcriptional inhibitor act D (n=6). Data presented mean &#194;&#177; SEM. * <br />                                            p&lt;0.05 vs. control. See Figure S4. <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                Cell Metab. Author manuscript; available PMC 2013 November 07. <br />                             Bayeva et al.                                                                                       Page 23 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            Figure 5. mTOR regulates TfR1 TTP <br />                                            (A) Schematic representation TfR1-3&#226;&#8364;&#8482;UTR-Luc construct IREs indicated white <br />                                            putative AREs grey. Luciferase assay TfR1-3&#226;&#8364;&#8482;UTR activity WT MEFs <br />                                            overexpressing TTP (B) TTP KO WT MEFs (C), normalized renilla luciferase <br />                                            (n=6). (D) mRNA levels TfR1 total RNA co-precipitated TTP IgG (control) <br />                                            antibodies HEK293 cells. Four primer sets targeting different regions near 3&#226;&#8364;&#8482;UTR of <br />                                            TfR1 gene used RNA co-IP assay normalized 18S internal control. <br />                                            Data presented fold enrichment IgG control (n=3). (E) mRNA levels TfR1 <br />                                            TTP WT KO MEFs treated rapamycin vehicle control (n=12). (F) mRNA <br />  <br />  <br />                                               Cell Metab. Author manuscript; available PMC 2013 November 07. <br />                             Bayeva et al.                                                                                      Page 24 <br />  <br />  <br />                                            levels ABCE1 Lias TTP WT KO MEFs rapamycin treatment <br />                                            (n=12). (G) TfR1 mRNA stability 3-hour incubation act D WT TTP KO <br />                                            MEFs presence absence rapamycin. Data presented fold change TfR1 <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            mRNA levels time point zero respective group (n=3&#226;&#8364;&#8220;6). (H) TfR1 mRNA levels <br />                                            TTP WT KO MEFs DFO treatment (n=6). (I) Cell death assessed <br />                                            propidium iodine (PI) Annexin V labeling flow cytometry TTP WT KO <br />                                            MEFs treated 250&#194;&#181;M DFO 250&#194;&#181;M 2,2-BPD 40 hours normalized the <br />                                            vehicle-treated control (n=4). (J) Cell death TTP KO MEFs 16-hour pre- <br />                                            treatment rapamycin incubated 250&#194;&#181;M DFO 250&#194;&#181;M 2,2-BPD 40 hours with <br />                                            rapamycin (n=4). Data presented mean &#194;&#177; SEM. * p&lt;0.05 vs. control, # <br />                                            p&lt;0.05 vs. rapamycin pre-treated control group. Rapa, rapamycin. See Figure S5. <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                               Cell Metab. Author manuscript; available PMC 2013 November 07. <br />                             Bayeva et al.                                                                                       Page 25 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            Figure 6. In vivo regulation iron homeostasis mTOR TTP <br />                                            Non-heme (A) heme (B) iron levels hearts c57 black WT mice treated 5 <br />                                            daily IP injections rapamycin, 10mg/kg (n=6), equal volume DMSO vehicle. (C) <br />                                            TfR1 Fpn1 mRNA levels hearts rapamycin-treated mice (n=6). (D) Western <br />                                            blot analysis rapamycin-treated mouse hearts. Densitometry analysis presented below <br />                                            Western blots (n=3). (E). Western blot analysis TfR1 protein hearts TTP/ <br />                                            TNFR1/2 KO (designated TTP KO) matched littermate WT control mice (designated <br />                                            TTP WT). Densitometry analysis presented right Western blot (n=3). (F) <br />                                            Non-heme iron levels hearts TTP KO WT mice (n=4). (G) Western blot <br />  <br />  <br />                                               Cell Metab. Author manuscript; available PMC 2013 November 07. <br />                             Bayeva et al.                                                                                         Page 26 <br />  <br />  <br />                                            analysis ferritin light heavy chains (FtL + FtH) Fpn1 proteins hearts of <br />                                            TTP KO WT mice. Densitometry analysis presented Western blots (n=4). <br />                                            (H) Model cellular iron regulation mTOR TTP. Data presented mean &#194;&#177; <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            SEM. * p&lt;0.05. See Figure S6. <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                               Cell Metab. Author manuscript; available PMC 2013 November 07. <br />                             Bayeva et al.                                                                                      Page 27 <br />  <br />  <br />  <br />  <br />                                                                                         Table 1 <br />                                                 Interaction TTP TfR1 mRNA <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                            RNA-CoIP experiment using specific TTP antibody control IgG antibody bait establishes physical <br />                            interaction TTP TfR1 mRNA. Four distinct sets primers designed target regions of <br />                            TfR1 mRNA adjacent 3&#226;&#8364;&#8482;UTR. Relative mRNA levels assessed qRT-PCR displayed as <br />                            fold enrichment IgG control. VEGF1 Pitx-2 used positive controls, &#206;&#178;2-microglobulin, <br />                            Fpn1, HPRT 18S rRNA used negative controls. See Figure S6 <br />  <br />                             Gene                    Relative Expression   Relative Expression   Fold Enrichment <br />                                                     IgG                   TTP                   Over IgG Control <br />  <br />                             Transferrin Receptor <br />  <br />                               TfR1-1                281.81                426.31                1.51 <br />  <br />                               TfR1-2                528.61                672.54                1.27 <br />  <br />                               TfR1-3                268.16                381.56                1.42 <br />  <br />                               TfR1-4                266.13                369.66                1.45 <br />  <br />                             Positive Controls <br />  <br />                               VEGF-1                1931.18               3678.42               1.90 <br />  <br />                               VEGF-2                2048.95               3982.25               1.94 <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                               Pitx2-1               2082.60               1960.18               0.94 <br />  <br />                               Pitx2-2               690.53                984.72                1.43 <br />  <br />                             Negative Controls <br />  <br />                               &#206;&#178;2MG                  22080.25              19099.78              0.87 <br />  <br />                     <br /> </body></html>